Last reviewed · How we verify
supplementary oxygen
At a glance
| Generic name | supplementary oxygen |
|---|---|
| Also known as | 100% oxygen gas with continous flow from wall outlet |
| Sponsor | LHL Helse |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease (NA)
- Tofacitinib for Treatment of Moderate COVID-19 (PHASE2)
- Optimising Neonatal Ventilation with Closed-loop Oxygen Control (NA)
- The Effect of Acute High Altitude Exposure on Rescuer Performance and Patient Care (NA)
- Effectiveness of Enhanced External Counterpulsation for Post-acute Stroke Patients (NA)
- New Procedure to Reduce Mother-newborn Separation (NA)
- A New Clinical Use of Ferumoxytol Nanoparticles: An Antibiofilm Treatment (PHASE4)
- Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- supplementary oxygen CI brief — competitive landscape report
- supplementary oxygen updates RSS · CI watch RSS
- LHL Helse portfolio CI